Please select a valid location from the dropdown
Clear All
Advanced search
Advanced Filters
  1. Search clinical trials
  2. Search results

Found 4 results for Hemophilia

Below is a list of actively recruiting clinical trials based on your search for "Hemophilia"

A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B (ATLAS-KIDS)

1 year - 11 years
Male
Phase 3
Interventional
This is a parallel, Phase 3, two-arm, open-label study to evaluate the efficacy and safety of treatment with fitusiran prophylaxis administered to male pediatric participants (aged 1 to Number of participants:Approximately 85 participants will be enrolled into the study:Approximately 60 fitusiran-naïve participants with severe hemophilia A or B, with or …
Check Eligibility

Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy (SYNOVIIIUS)

All genders
Phase 4
Interventional
The objective of the study is to assess the improvement of synovial hypertrophy during the 12 months of efanesoctocog alfa prophylaxis once per week (QW) in joints with existing evidence of synovial hypertrophy in participants with hemophilia A. The study duration for each participant is approximately 12 months.
About the study

A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab

Male
Phase 4
Interventional
This is an exploratory, single group, Phase 4, study to assess treatment with fitusiran prophylaxis after switching from emicizumab prophylaxis.This study aims to evaluate the safety and tolerability of switching to fitusiran after a transition period from the last dose of emicizumab. The study will be conducted in male participants …
About the study

ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders

All genders
Observational
In parallel with the growth of ATHN's clinical studies, the number of new therapies for all blood disorders is increasing significantly. Some of the recently FDA-approved therapies for congenital and acquired hematologic conditions have not yet demonstrated long-term safety and effectiveness beyond the pivotal trials that led to their approval. …
About the study